STOCK TITAN

Perspective Therapeutics (CATX) EPS by Year

CATX NYSE

Perspective Therapeutics, Inc. lost $1.40 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $1.25 per diluted share. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Perspective Therapeutics, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$1.40
YoY n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

CATX EPS (Diluted) by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
EPS (Diluted)-$1.25-$1.40n/m-$1.23-$1.74N/A-$0.30-$0.50n/m-$0.80n/m-$1.20n/m-$1.10n/m-$0.90n/m-$0.70n/m-$1.60n/m-$1.10n/m-$1.20n/m-$1.10

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

CATX EPS (Diluted) by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
EPS (Diluted)-$0.27-$0.22-$0.25n/m-$0.51n/m-$0.35n/m-$0.29n/m-$0.25n/m-$0.61n/m-$0.21-$0.18-$0.25-$0.91

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Perspective Therapeutics, Inc. financials

Frequently Asked Questions

Perspective Therapeutics, Inc. lost $1.40 per diluted share in fiscal year 2025.

Perspective Therapeutics, Inc. (CATX) reported a loss of $1.23 per diluted share in fiscal year 2024 and a loss of $1.40 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Perspective Therapeutics, Inc. (CATX) reported a loss of $1.25 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, Perspective Therapeutics, Inc. (CATX) diluted earnings per share went from -$1.10 in fiscal year 2011 to -$1.40 in fiscal year 2025.

Perspective Therapeutics, Inc. (CATX) reported -$0.27 in diluted earnings per share in Q3 2026.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Perspective Therapeutics, Inc. (CATX) reported on that line in every period on record.